Directly observed antiretroviral therapy in substance abusers receiving methadone maintenance therapy does not cause increased drug resistance

James C.M. Brust, Alain H. Litwin, Karina M. Berg, Xuan Li, Moonseong Heo, Julia H. Arnsten

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Direct observation of antiretroviral therapy (DOT) can increase adherence rates in HIV-infected substance users, but whether this affects the development of antiretroviral drug resistance has not been fully explored. We conducted a 24-week randomized controlled trial of methadone clinic-based antiretroviral DOT compared with treatment as usual (TAU) among antiretroviral-experienced substance users. To examine the development of new resistance mutations, we identified all participants with an amplifiable resistance test at both baseline and either week 8 or week 24. We compared the development of new drug resistance mutations between participants in the two arms of the trial. Among the 77 participants enrolled in the parent trial, antiretroviral DOT was efficacious for improving adherence and decreasing HIV viral load. Twenty-one participants had a detectable HIV viral load at both baseline and a second time point. Of these, nine developed new drug resistance mutations not seen at baseline (three in the DOT arm and six in the TAU arm; p = 0.27). Overall, five subjects in the TAU arm developed major mutations correlating with their current antiretroviral regimen, while no subjects in the DOT arm developed such mutations. Direct observation of antiretroviral therapy was associated with improved adherence and viral suppression among methadone maintained HIV-infected substance users, but was not associated with an increase in the development of antiretroviral drug resistance. DOT should be considered for substance users attending methadone maintenance clinics who are at high risk of nonadherence.

Original languageEnglish (US)
Pages (from-to)535-541
Number of pages7
JournalAIDS Research and Human Retroviruses
Volume27
Issue number5
DOIs
StatePublished - May 1 2011

Fingerprint

Directly Observed Therapy
Methadone
Drug Resistance
Observation
Mutation
HIV
Therapeutics
Viral Load
Randomized Controlled Trials

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Infectious Diseases

Cite this

Directly observed antiretroviral therapy in substance abusers receiving methadone maintenance therapy does not cause increased drug resistance. / Brust, James C.M.; Litwin, Alain H.; Berg, Karina M.; Li, Xuan; Heo, Moonseong; Arnsten, Julia H.

In: AIDS Research and Human Retroviruses, Vol. 27, No. 5, 01.05.2011, p. 535-541.

Research output: Contribution to journalArticle

@article{c8581a0bac0045fe99a428b08c94d021,
title = "Directly observed antiretroviral therapy in substance abusers receiving methadone maintenance therapy does not cause increased drug resistance",
abstract = "Direct observation of antiretroviral therapy (DOT) can increase adherence rates in HIV-infected substance users, but whether this affects the development of antiretroviral drug resistance has not been fully explored. We conducted a 24-week randomized controlled trial of methadone clinic-based antiretroviral DOT compared with treatment as usual (TAU) among antiretroviral-experienced substance users. To examine the development of new resistance mutations, we identified all participants with an amplifiable resistance test at both baseline and either week 8 or week 24. We compared the development of new drug resistance mutations between participants in the two arms of the trial. Among the 77 participants enrolled in the parent trial, antiretroviral DOT was efficacious for improving adherence and decreasing HIV viral load. Twenty-one participants had a detectable HIV viral load at both baseline and a second time point. Of these, nine developed new drug resistance mutations not seen at baseline (three in the DOT arm and six in the TAU arm; p = 0.27). Overall, five subjects in the TAU arm developed major mutations correlating with their current antiretroviral regimen, while no subjects in the DOT arm developed such mutations. Direct observation of antiretroviral therapy was associated with improved adherence and viral suppression among methadone maintained HIV-infected substance users, but was not associated with an increase in the development of antiretroviral drug resistance. DOT should be considered for substance users attending methadone maintenance clinics who are at high risk of nonadherence.",
author = "Brust, {James C.M.} and Litwin, {Alain H.} and Berg, {Karina M.} and Xuan Li and Moonseong Heo and Arnsten, {Julia H.}",
year = "2011",
month = "5",
day = "1",
doi = "10.1089/aid.2010.0181",
language = "English (US)",
volume = "27",
pages = "535--541",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - Directly observed antiretroviral therapy in substance abusers receiving methadone maintenance therapy does not cause increased drug resistance

AU - Brust, James C.M.

AU - Litwin, Alain H.

AU - Berg, Karina M.

AU - Li, Xuan

AU - Heo, Moonseong

AU - Arnsten, Julia H.

PY - 2011/5/1

Y1 - 2011/5/1

N2 - Direct observation of antiretroviral therapy (DOT) can increase adherence rates in HIV-infected substance users, but whether this affects the development of antiretroviral drug resistance has not been fully explored. We conducted a 24-week randomized controlled trial of methadone clinic-based antiretroviral DOT compared with treatment as usual (TAU) among antiretroviral-experienced substance users. To examine the development of new resistance mutations, we identified all participants with an amplifiable resistance test at both baseline and either week 8 or week 24. We compared the development of new drug resistance mutations between participants in the two arms of the trial. Among the 77 participants enrolled in the parent trial, antiretroviral DOT was efficacious for improving adherence and decreasing HIV viral load. Twenty-one participants had a detectable HIV viral load at both baseline and a second time point. Of these, nine developed new drug resistance mutations not seen at baseline (three in the DOT arm and six in the TAU arm; p = 0.27). Overall, five subjects in the TAU arm developed major mutations correlating with their current antiretroviral regimen, while no subjects in the DOT arm developed such mutations. Direct observation of antiretroviral therapy was associated with improved adherence and viral suppression among methadone maintained HIV-infected substance users, but was not associated with an increase in the development of antiretroviral drug resistance. DOT should be considered for substance users attending methadone maintenance clinics who are at high risk of nonadherence.

AB - Direct observation of antiretroviral therapy (DOT) can increase adherence rates in HIV-infected substance users, but whether this affects the development of antiretroviral drug resistance has not been fully explored. We conducted a 24-week randomized controlled trial of methadone clinic-based antiretroviral DOT compared with treatment as usual (TAU) among antiretroviral-experienced substance users. To examine the development of new resistance mutations, we identified all participants with an amplifiable resistance test at both baseline and either week 8 or week 24. We compared the development of new drug resistance mutations between participants in the two arms of the trial. Among the 77 participants enrolled in the parent trial, antiretroviral DOT was efficacious for improving adherence and decreasing HIV viral load. Twenty-one participants had a detectable HIV viral load at both baseline and a second time point. Of these, nine developed new drug resistance mutations not seen at baseline (three in the DOT arm and six in the TAU arm; p = 0.27). Overall, five subjects in the TAU arm developed major mutations correlating with their current antiretroviral regimen, while no subjects in the DOT arm developed such mutations. Direct observation of antiretroviral therapy was associated with improved adherence and viral suppression among methadone maintained HIV-infected substance users, but was not associated with an increase in the development of antiretroviral drug resistance. DOT should be considered for substance users attending methadone maintenance clinics who are at high risk of nonadherence.

UR - http://www.scopus.com/inward/record.url?scp=79955781629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955781629&partnerID=8YFLogxK

U2 - 10.1089/aid.2010.0181

DO - 10.1089/aid.2010.0181

M3 - Article

C2 - 20854173

AN - SCOPUS:79955781629

VL - 27

SP - 535

EP - 541

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 5

ER -